Previous research had suggested some benefit for kidney transplant recipients with a history of type 2 diabetes who took the medications, originally designed to treat diabetes, at some point after their transplant and then experienced slower declines in kidney function than those who did not
Others report symptoms more consistent with a migraine, such as throbbing pain, light or sound sensitivity, or nausea accompanying the headache
Two doses of 10mg in close succession would deliver 20mg to your system, well above the maximum approved dose of 15mg, and would significantly increase side effect risk
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide acts on GLP-1 receptors alone and tirzepatide targets both GIP and GLP-1 receptors
Clinical trials show patients lose an average of 15% of body weight, with some losing up to 22% depending on dose and individual response
2019 update to: management of hyperglycemia in type 2 diabetes, 2018
